Duquesne Family Office is the personal investment firm of Stanley F. Druckenmiller, founded in 2010 after he closed his hedge fund Duquesne Capital. It manages the Druckenmiller family's wealth using a concentrated, macro-driven investment approach across public equities, venture investments, commodities, and credit opportunities.
40% of their portfolio is in Healthcare. Deal activity decreased year-over-year (1 deals in the last 12 months vs 3 prior). Their most common stage is series-c (40% of deals). Average disclosed round size is $80.5M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series C
Last 12 Mo
1
Team
Sue Meng
Partner and Managing Director
Chance Cooley
Analyst
Blake Balda
Investor
Dan Berardo
Investor
Daniel Du
Investor
Emily Park
Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 MyOme, Inc. | Unknown | — | Dec 2025 |
 Ledgebrook | Series C | $65M | Jun 2025 |
| QQ.ANT GmbH | Series A | $80M | Jan 2025 |
 Precision Neuroscience | Series C | $102M | Dec 2024 |
 MetOx | Series B | $15M | Nov 2024 |
 C2i Genomics | Series C | $100M | Apr 2021 |
| C2i Genomics | Series B | $100M | Apr 2021 |
 SonoThera | Series B | $125M | — |
 Lean | Series B | $67.5M | — |
| RRatio Therapeutics Inc. | Series C | $70M | — |
Top Co-Investors
Last updated: 9 September 2026